Pfizer (PFE) Net Margin (2009 - 2026)

Pfizer (PFE) posted quarterly Net Margin of 0.09% for Q1 2026, down 108.18% quarter-over-quarter from 1.1% in Q2 2025.

Pfizer (PFE) Net Margin (2009 - 2026) Analysis & Trends

Pfizer (PFE) has reported Net Margin for 18 consecutive years, with 0.09% the latest figure, recorded in Q1 2026.

In Q1 2026, Net Margin changed N/A year-over-year to 0.09%; the TTM figure through Mar 2026 stood at 0.5% (down 52.0% YoY), while the FY2025 annual figure was 0.27%, up 14.0% from the prior year.
Net Margin retreated to 0.09% in Q1 2026 per PFE's latest filing, from 1.1% in the prior quarter.
Across five years, Net Margin topped out at 1.1% in Q2 2025 and bottomed at 0.76% in Q4 2023.
Historically, Net Margin has averaged 0.04% across 5 years, with a median of 0.03% in 2024.
Annual changes were most pronounced in 2022 — Net Margin jumped 137 bps — and 2023, when it fell 18 bps.
Pfizer's Net Margin stood at 0.12% in 2022, then slumped by 718 bps to 0.76% in 2023, then surged by 98 bps to 0.02% in 2024, then soared by 6406 bps to 1.1% in 2025, then tumbled by 108 bps to 0.09% in 2026.
Business Quant data shows PFE's Net Margin at 0.09% in Q1 2026, 1.1% in Q2 2025, and 0.02% in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	21.86%
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	21.28%
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	-8.05%
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	22.65%
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	16.30%
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	23.62%
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	-134.51%
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	-1.58%
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	5.17%
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	2.96%

Download Data